NEWS & PRESENTATIONS

News & Press Releases

November 26, 2019

Incysus Therapeutics to Participate in Evercore ISI HealthCONx Conference

Incysus Therapeutics, Inc. today announced that William Ho, President and Chief Executive Officer of Incysus will participate in a panel, entitled, “Cell Therapy, Make Room,” during the 2nd Annual Evercore ISI HealthCONx Conference on Wednesday, December 4 at 11:45 a.m. Eastern Time.  The conference will be held at the Four Seasons Hotel Boston, MA.

November 21, 2019

Incysus Therapeutics to Present at the 2019 Society for Neuro-Oncology (SNO) Annual Meeting

Incysus Therapeutics, Inc. today announced that data related to the preclinical characterization of its therapeutic agent will be presented during the 24th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology.  Dr. Burt Nabors, the study Principal Investigator and Director of the Neuro-Oncology program for the O’Neal Comprehensive Cancer Center at the University of Alabama
at Birmingham (UAB) will present the data on Friday, November 22 at the JW Marriott Desert Ridge Hotel.

November 7, 2019

Incysus Therapeutics to Present at the New York Oncology Investor Conference

Incysus Therapeutics, Inc. today announced that the Company will present at the 2019 New York Oncology Investor Conference being held in New York City on November 12th-13th. William Ho, President and Chief Executive Officer of Incysus Therapeutics, will present a company overview on Tuesday, November 12, 2019 at 10:40 a.m. Eastern Time

October 22, 2019

Incysus Therapeutics to Present at the 2019 BIO Investor Forum

Incysus Therapeutics, Inc. today announced that the company will present at the 2019 BIO Investor Forum being held in San Francisco, CA on October 22nd.  William Ho, President and Chief Executive Officer of Incysus, will present a company overview. 

September 10, 2019

Incysus Therapeutics to Present at 5th Annual CAR-TCR Summit

Incysus Therapeutics, Inc. today announced that the company will present at the 5th Annual CAR-TCR Summit being held September 10-13, 2019 in Boston, MA.  William Ho, CEO is scheduled to participate in a Discovery panel session on Thursday, September 12, 2019, at 12:30 p.m. EDT and Lawrence Lamb, PhD, CSO will present at a scientific symposium in the Translation track at 3:32 p.m. EDT.

September 4, 2019

Incysus Therapeutics to Present at the BioCentury NewsMakers in the Biotech Industry Conference

Incysus Therapeutics, Inc. today announced that it has been invited to present at the BioCentury 26th Annual NewsMakers in the Biotech Industry Conference on Friday, September 6, 2019, in New York.  

August 6, 2019

Incysus Therapeutics Strengthens Board of Directors with Appointment of Pharmaceutical Veteran Peter C. Brandt

Incysus Therapeutics, Inc. today announced the appointment of Peter C. Brandt to its Board of Directors. With his many decades of leadership in the life sciences, including 28 years at Pfizer, Peter brings invaluable expertise that will further strengthen our team at this important time as we anticipate initiating the first clinical trials of our γδ T cell technologies. 

July 2, 2019

Incysus Therapeutics Appoints Rozanna Yaing as Senior Vice President, Quality and Regulatory Affairs

Incysus Therapeutics, Inc. today announced the appointment of Rozanna Yaing, as Senior Vice President, Quality and Regulatory Affairs.  Ms. Yaing will be responsible for quality and regulatory affairs across Incysus’ portfolio and will serve on the Company’s Executive Committee.

June 19, 2019

Incysus Therapeutics Announces Publication of U.S. Patent for Drug Resistant Immunotherapy (DRI) Technology

Incysus Therapeutics, Inc. today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 10,322,145 titled “Drug Resistant Immunotherapy for Treatment of a Cancer.”  The patent covers the treatment of brain cancer with the combination of certain chemotherapies and a γδ T cell genetically modified to confer chemotherapy resistance. The full text of this patent is available from the USPTO website (http://bit.ly/2ZxbxKe).

May 21, 2019

Incysus Therapeutics to Present at Jefferies 2019 Global Healthcare Conference

Incysus Therapeutics, Inc. today announced that William Ho, Chief Executive Officer and co-founder will present and host investor meetings at the Jefferies 2019 Global Healthcare Conference being held in New York, NY on June 4-7.  The presentation is scheduled for Friday, June 7 at 9:00am Eastern Time.  The webcast can be accessed here:  http://bit.ly/ICYSJefco2019

May 2, 2019

Lawrence Lamb, Ph.D., Incysus Therapeutics Scientific Co-Founder to Present at Allogeneic Cell Therapies Summit 2019 (ACTS)

Incysus Therapeutics, Inc. today announced Lawrence S. Lamb, PhD, scientific co-founder and Chief Scientific Officer of Incysus will present at a scientific symposium on Thursday, May 9, 2019 during the Allogeneic Cell Therapies Summit 2019 (ACTS), in Boston, Massachusetts.  The session titled, “Driving the Road to Off-the-Shelf Allogeneic γδ Cell Therapies” will discuss and differentiate Incysus' development programs in the γδ T cell space.

April 3, 2019

Incysus Therapeutics Appoints Melissa Beelen as Vice President, Clinical Operations

Incysus Therapeutics, Inc. today announced the appointment of Melissa Beelen, as Vice President, Clinical Operations.  Ms. Beelen will be responsible for strategic leadership and head clinical operations as the company advances its first programs into the clinic.

April 1, 2019

Incysus Therapeutics Announces FDA Clearance of IND Application for a Novel Gamma-Delta (γδ) T Cell Therapy for Treatment of Patients with Newly-Diagnosed Glioblastoma

Incysus Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for the clinical study of a genetically modified γδ T cell in combination with chemotherapy for the treatment of patients with newly-diagnosed glioblastoma (GBM).  This represents the first genetically modified γδ T cell product candidate that the FDA has cleared for a clinical trial. 

March 19, 2019

Incysus Therapeutics to Present New Data at the American Association for Cancer Research (AACR) Annual Meeting 2019

Incysus Therapeutics, Inc. today announced that Lawrence S. Lamb, PhD, Incysus' Chief Scientific Officer, will present new preclinical data on Incysus’ drug resistant immunotherapy (DRI) approach during the AACR Annual Meeting.  The poster presentation (abstract # - 2262) will be held on Monday April 1, 2019 during the Combination Immunotherapies I session.

January 3, 2019

Gamma-Delta T Cell Immunotherapy Pioneer, Lawrence Lamb, PhD, to Join Incysus Therapeutics as Chief Scientific Officer

Incysus Therapeutics, Inc. today announced that Lawrence S. Lamb, PhD has joined the company as its Executive Vice President and Chief Scientific Officer.  Dr. Lamb will lead the company’s research and development programs and will be responsible for setting scientific strategy.

January 3, 2019

Incysus Therapeutics Completes Series A Financing and Announces the Appointment of Travis Whitfill, MPH to its Board of Directors

Incysus Therapeutics, Inc. today announced the closing of a $10 million Series A round of financing. Proceeds from the financing will be used to expand the management team and support advancement of the Company’s drug-resistant immunotherapy technology in both clinical and pre-clinical programs.  The company expects to initiate its first two Phase 1 clinical programs in the first half of 2019.

November 28, 2018

Incysus Therapeutics Announces Presentations at 2018 ASH and HAPLO Annual Meetings

Incysus Therapeutics, Inc. announced that data related to the Company’s ongoing programs will be presented at the 60th American Society of Hematology Annual Meeting & Exposition (ASH) and at the 6th annual Haploidentical Transplant Symposium (HAPLO2018) this week in San Diego, CA. 

November 15, 2018

Gamma-Delta (γδ) T Cell Therapy Combined with Checkpoint Inhibition Shows Potential Synergies In Vitro for Treatment of Glioblastoma

Incysus Therapeutics, Inc. announced that Lawerence S. Lamb, PhD, a Scientific Co-Founder of Incysus will present a poster during the 23rd Annual Scientific Meeting of the Society for Neuro-Oncology (SNO) in New Orleans. The preclinical data demonstrates that Incysus' technology using gene-modified γδ T cells, in combination with checkpoint inhibitor antibodies has the potential to drive synergies to increase immune mediated killing of glioblastoma.  

October 22, 2018

Incysus Therapeutics to Participate in Panel at the 2018 Life Sciences Summit

Incysus Therapeutics, Inc. announced that William Ho, President and Chief Executive Officer will join a distinguished group of panelists including representatives from Merck, Bristol-Myers Squibb, Quentis Therapeutics and Memorial Sloan-Kettering Cancer Center during the “Therapeutic Insight: Immuno-Oncology’s Next Generation Therapies” panel at the 2018 Life Sciences Summit

October 16, 2018

Incysus Therapeutics to Present at the 2018 BIO Investor Forum

Incysus Therapeutics, Inc. announced that William Ho, a Co-Founder of Incysus, President and CEO will present a company overview at the annual BIO Investor Forum conference being held in San Francisco.  The presentation will be on Thursday, October 18, 2018 at 10:15am PDT in the Elizabethan A room at the Westin St. Francis Hotel.

August 16, 2018

Lawrence Lamb, Ph.D. Incysus Therapeutics Scientific Co-Founder to Present at 10th Annual Bioprocessing Summit

Incysus Therapeutics, Inc. announced that Lawrence Lamb, PhD, a Scientific Co-Founder of Incysus, will present at a scientific symposium today, on Thursday, August 16, 2018 during the 10th Annual Bioprocessing Summit, in Boston, Massachusetts.  The discussion will focus on the scale-up and GMP manufacturing of gene-modified γδ T cells for a Phase I trial.

June 8, 2018

Incysus Therapeutics Scientific Co-Founder Lawrence Lamb, PhD to Present at 8th International Gamma-Delta T Cell Conference

Incysus Therapeutics, Inc. announced that Lawrence Lamb, PhD, a Scientific Co-Founder of Incysus, will present at a scientific symposium on June 10, 2018 during the 8th International Gamma-Delta T Cell Conference, in Bordeaux, France.  Dr. Lamb's session is titled: “Targeting of chemotherapy-induced NKG2DL by localized repetitive γδ T cell infusions: a rational therapeutic design for elimination of minimal residual primary high grade gliomas”.

May 22, 2018

Incysus Moves Its Corporate Domicile to Delaware

Incysus, Ltd. announced that effective May 7, 2018 it had moved its corporate domicile from Bermuda to the United States of America in the State of Delaware.  Advancing ahead, the corporate name will now be Incysus Therapeutics, Inc.  Management expects that these changes will help support our growth strategy without affecting the day-to-day business and operations of the organization.

May 16, 2018

Incysus Therapeutics' Scientific Co-Founder Lawrence Lamb, PhD and Marcela Maus, MD, PhD to Co-Chair Gene Therapy Symposium During 2018 ASGCT Meeting

Dr. Lamb and Dr. Maus will Co-Chair a Symposium Titled: "Tipping Point: Gene Therapy Entering the Market” on Friday, May 18, 2018 at 8:00am CDT at the American Society of Gene and Cell Therapy (ASGCT) Meeting in Chicago.  Dr. Bruce Levine, PhD, also member of Incysus' Scientific Advisory Board will also present during the session.

May 14, 2018

Incysus Announces Appointment of Joy Bessenger as Senior Vice President, Finance and Strategy

Joy E. Bessenger has been appointed Senior Vice President, Finance and Strategy to help Incysus advance through its next stage of growth as it prepares to initiate clinical programs in 2018

March 21, 2018

Incysus to Present at BioCentury Future Leaders Conference

William Ho, Chief Executive Officer of Incysus will present at the 25th Annual BioCentury Future Leaders Conference on Friday, March 23, 2018 at 2:30pm EDT at the Millennium Broadway Hotel and Conference Center in New York

March 20, 2018

Incysus to Present Scientific Overview at the 2018 CAR-T Congress USA Meeting

Dr. Lawrence Lamb, to Present Adoptive Gamma-Delta T cell Immunotharpy as a Strategy for Eliminating Residual Malignancy at CAR-T Congress USA Meeting in Boston

February 13, 2018

Incysus Presents Positive Data on Drug-Resistant Immunotherapy for Glioblastoma at AACR CNS Immunotherapy Conference

Dr. Lawrence Lamb, PhD to present at a Plenary Session of the Immunobiology of Primary and Metastatic CNS Cancer: Multidisciplinary Science to Advance Cancer Immunotherapy, a special AACR conference being held in San Diego, California

January 9, 2018

Incysus Submits Second Investigational New Drug Application for Gamma-Delta T Cell Immunotherapy Candidate

IND to support Phase 1 safety and activity study of Drug Resistant Immunotherapy for the treatment of glioblastoma.

November 30, 2017

Incysus Announces Appointment of Siraj Ali, MD, PhD to its Scientific Advisory Board

Incysus announced the addition of Siraj Ali, MD, PhD to its Scientific Advisory Board (SAB).  Dr. Ali is a physician-scientist and leads translational research efforts at Foundation Medicine.  He focuses on identifying predictive biomarkers for targeted anti-neoplastic and cancer immunotherapies, which encompasses both basic cancer biology and exceptional responders in the clinic.

October 17, 2017

Incysus Announces FDA Clearance of IND Application for a Phase I Study of a Gamma-Delta (γδ) T Cell Leukemia and Lymphoma Immunotherapy

Incysus announced the clearance of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) allowing the initiation of a Phase I clinical trial testing the allogeneic delivery of expanded and activated gamma-delta (γδ) T cells for the treatment of patients with blood cancers following haploidentical stem cell transplantation.

October 12, 2017

CHEMO-PROOF T CELLS - By Lauren Martz, Senior Writer, BioCentury

Incysus and our innovative technology were profiled in the October 12, 2017 edition of BioCentury Innovations.

September 19, 2017

Incysus Submits Investigational New Drug (IND) Application for Allogeneic Gamma-Delta T Cell Immunotherapy for Leukemia and Lymphoma

Incysus today announced the submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to conduct a first-ever Phase I study of expanded and activated gamma-delta (γδ) T cells for the treatment of patients with blood cancers following haploidentical stem cell transplantation.

September 7, 2017

Incysus Collaborators Publish Review in Bone Marrow Transplantation

Incysus' scientific co-founder Dr. Lawrence S. Lamb, PhD and collaborator Dr. Ayman Saad, MD at the University of Alabama at Birmingham (UAB) published in print a review of current and emerging strategies of T cell depletion in allogeneic hematopoietic stem cell transplantation in the journal Bone Marrow Transplantation (www.nature.com/bmt), (2017) 52, 1241-1248.

August 24, 2017

Incysus Announces Formation of Scientific Advisory Board

Incysus announces the formation of its inaugural Scientific Advisory Board (SAB) with a world-leading group of experts in the areas of immunology, cell therapy and oncology.

August 23, 2017

Incysus Scientific Co-Founder to Present at Immuno-Oncology Summit

Incysus' collaborator and scientific co-founder, Dr. Lawrence S. Lamb, MN, PhD from the University of Alabama at Birmingham (UAB), will be presenting at the Immuno-Oncology Summit in Boston on Wednesday, August 30th, 2017 (http://immuno-oncologysummit.com/T-Cell/).

May 4, 2017

UAB spinoff targets cancer with drug-resistant immunotherapy, a novel approach to fighting tumors

The University of Alabama at Birmingham (UAB), Emory University and Children's Healthcare of Atlanta have licensed technology to Incysus to develop a novel cellular therapy called Drug-Resistant Immunotherapy or DRI.

April 12, 2017

Incysus Granted European Patent Covering its Drug Resistant Immunotherapy (DRI) Technology 

The European Patent Office granted EU Patent No. 2496244 covering claims related to methods of combining chemotherapy with immunotherapy.

March 24, 2017

Incysus Announces Preclinical Data Presentations of γδ T Cell Immunotherapy Programs at Upcoming Medical Conferences

Incysus' academic collaborators present preclinical data highlighting their γδ T cell immunotherapy programs at major medical conferences.

©2019 by Incysus Therapeutics, Inc.  |  info@incysus.com  |  Privacy Policy  |  Terms of Use